Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial

Pediatric Diabetes

Volumn 19, Issue 3, 2018, Pages 410-419

  Elding Larsson, Helena ^a   Lundgren, Markus ^a   Jonsdottir, Berglind ^a   Cuthbertson, David ^b   Krischer, Jeffrey ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

autoimmunity; GAD Alum; prevention; type 1 diabetes

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AUTOANTIBODY; AUTOANTIGEN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; PLACEBO;

ADOLESCENT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NAUSEA; PANCREAS ISLET; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; STOMACH PAIN; TREATMENT OUTCOME; VOMITING; CHEMISTRY; DISEASE EXACERBATION; IMMUNOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; AUTOANTIGENS; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS;

EID: 85043388547     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12611     Document Type: Article

References (27)

1. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–2479.
2. Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58:980–987.
3. Diabetes Prevention Trail-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–1691.
4. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–931.
5. Nanto-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372:1746–1755.
6. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care. 2005;28:1068–1076.
7. Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34:2347–2352.
8. Jacobsen L, Schatz D. Current and future efforts toward the prevention of type 1 diabetes. Pediatr Diabetes. 2016;17 (suppl 22):78–86.
9. Bonifacio E, Ziegler AG, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015;313:1541–1549.
10. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes. 1998;47:894–899.
11. Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med. 1996;2:1348–1353.
12. Uibo R, Lernmark A. GAD65 autoimmunity-clinical studies. Adv Immunol. 2008;100:39–78.
13. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications. 2005;19:238–246.
14. Agardh CD, Lynch KF, Palmer M, Link K, Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia. 2009;52:1363–1368.
15. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359:1909–1920.
16. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012;366:433–442.
17. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011;378:319–327.
18. Krause S, Landherr U, Agardh CD, et al. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial. Diabetes Care. 2014;37:1675–1680.
19. Hjorth M, Axelsson S, Ryden A, Faresjo M, Ludvigsson J, Casas R. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol. 2011;138:117–126.
20. Axelsson S, Cheramy M, Akerman L, Pihl M, Ludvigsson J, Casas R. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care. 2013;36:3418–3424.
21. Pihl M, Akerman L, Axelsson S, et al. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes. Clin Exp Immunol. 2013;172:394–402.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):S81–S90.
23. Elding Larsson H, Larsson C, Lernmark A, DiAPREV-IT Study Group. Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention. Acta Diabetol. 2015;52:473–481.
24. Andersson C, Carlsson A, Cilio C, et al. Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study. Pediatr Diabetes. 2013;14:341–349.
25. Andersson C, Larsson K, Vaziri-Sani F, et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity. 2011;44:394–405.
26. Agardh D, Borulf S, Lernmark A, Ivarsson SA. Tissue transglutaminase immunoglobulin isotypes in children with untreated and treated celiac disease. J Pediatr Gastroenterol Nutr. 2003;36:77–82.
27. Coppieters KT, Sehested Hansen B, von Herrath MG. Clinical potential of antigen-specific therapies in type 1 diabetes. Rev Diabet Stud. 2012;9:328–337.